Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002067 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
A Phase 3 study of HIV Infections and Cachexia, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Study locations
NCT00002067 is a Phase 3 study of HIV Infections and Cachexia that has completed, run by Bristol-Myers Squibb. The trial reports 14 study locations across 6 states.
The verdict
NCT00002067, a Phase 3 study of HIV Infections and Cachexia, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14
- Study locations
Study Summary
To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.
Conditions Studied
Interventions
- DRUG Megestrol acetate
Study Locations (14)
California
- Dr Mark Goldstein - Los Angeles
- Summitt Med Ctr / San Francisco Gen Hosp - Oakland
- Palo Alto Veterans Adm Med Ctr / Stanford Univ - Palo Alto
- Eisenhower Med Ctr - Rancho Mirage
- UCD Med Ctr - Sacramento
- San Francisco AIDS Clinic / San Francisco Gen Hosp - San Francisco
- San Francisco Veterans Administration Med Ctr - San Francisco
Florida
- Miami Veterans Administration Med Ctr - Miami
- Univ of South Florida - Tampa
New York
- Mem Sloan - Kettering Cancer Ctr - New York
- SUNY / Health Sciences Ctr at Syracuse - Syracuse
Colorado
- Denver Public Health Dept - Denver
Illinois
- Northwestern Univ Med School - Chicago
Washington
- Northwest Family Ctr at the Harbor View Med Ctr - Seattle
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002067
The ClinicalTrials.gov registry entry for NCT00002067 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Megestrol acetate is the first listed.
NCT00002067 reports 14 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT00002067 about?
NCT00002067 is a clinical study titled "A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia". To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients ...
What is the current status of trial NCT00002067?
This trial is currently completed. It is a Phase 3 study.
What conditions does trial NCT00002067 study?
This clinical trial studies the following conditions: HIV Infections, Cachexia, Anorexia.
What interventions are being tested in trial NCT00002067?
The interventions under investigation include: Megestrol acetate (DRUG).
Who is sponsoring clinical trial NCT00002067?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002067 being conducted?
This trial has 14 study locations across California, Colorado, Florida, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.